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Summary 
Disulfide-stabilized Fvs (dsFv) are recombinant Fv 
fragments of antibodies in which the Inherently unsta- 
ble VH-VL heterodimer is stabilized by an lnterchain 
disulfide bond engineered between structurally con- 
served framework positions. We now design and pro- 
duce a disulfide-stabilized Fv of a T cell receptor. It is 
composed of Vu and V3 varlable domains of the 284 
TCR stabilized by a disulflde bond between framework 
residues of the TCR Fv at a site corresponding to that 
used for disulfide stabilization of antibody Fvs. For 
ease of production and detection, the TCRdsFv was 
fused to a truncated form of Pseudomonas exotoxin 
(PE33). The TCR(dsFv) retains its native conformation 
and is much more stable than a TCR scFv. Moreover, it 
is functional in biological assays. Because successful 
disulfide stabilization of the TCR Fv by the positions 
used for antibody Fv stabilization would not occur un- 
less the mutated residues in TCR Fv are at positions 
closely similar to those in antibody Fvs, most likely 
within less than 1.5 A, these results provide very 
strong experimental evidence for the structural simi- 
larlty between lmmunoglobulin and TCR antigen- 
binding variable domains. 
introduction 
The T cell antigen receptor (TCR) is a membrane-bound 
receptor composed of two chains, a and 8, each consisting 
of an N-terminal variable region 01) and a C-terminal con- 
stant region (C) (Davis and Bjorkman, 1988; Chothia et 
al., 1988; Novotnyet al., 1988; Claverieet al., 1989). Analy- 
sis of the sequences of the TCR chains indicate that they 
have a framework closely related to that of immunoglobu- 
lins (Davis and Bjorkman, 1988; Chothia et al., 1988; Kro- 
nenberg et al., 1988). Further comparisons of the V chains 
of TCRs with V regions of immunoglobulin Gs (IgGs) indi- 
cated TCR variable domains have four hypervariable re- 
gions, three of which can be aligned with the complemen- 
tarity-determining regions (CDR) of IgGs to produce a 
Fab-like model of the TCR (Davis and Bjorkman, 1988; 
Chothia et al., 1988; Kronenberg et al., 1988; Jores et al., 
1990). Thus, it was proposed that the three-dimensional 
structure of TCR should be similar to the structure of anti- 
bodies (Davis and Bjorkman, 1988; Chothia et al., 1988; 
Novotny et al., 1988; Claverie et al., 1989; Kronenberg et 
al., 1988; Jores et al., 1990). However, the three-dimen- 
sional structure of the TCR a8 heterodimer has not yet 
been determined, in part because crystallography re- 
quires the production of relatively large amounts of a solu- 
ble form of this complex. Isolation of the soluble a8 hetero- 
dimer is difficult because the a and 8 chains are both 
type transmembrane proteins and are not soluble in the 
absence of detergent (Davis and Bjorkman, 1988). To cir- 
cumvent this problem, several genetic engineering-based 
approaches have been used toobtain recombinant soluble 
TCRs in significant quantities. These include the produc- 
tion of TCR chains truncated prior to the transmembrane 
domain (Gascoigne, 1990), hybrid molecules composed 
of the TCR and the constant domain of immunoglobulin 
(Weber et al., 1992; Gregoire et al., 1991) and altered 
forms of TCR that can be cleaved from the plasma mem- 
brane (Lin et al., 1990; Engel et al., 1992). The success 
in the expression of single-chain antibody variable do- 
mains in Escherichia coli (Huston et al., 1988, 1991; Bird 
et al., 1988) and the postulated structural similarities be- 
tween IgGs and TCRs led to the construction and expres- 
sion of the TCR variable domains as a single-chain mole- 
cule (SCFV) in which Va and Vp are connected by a peptide 
linker (Novotny et al., 1991; Soo Hoo et al., 1992; Ward, 
1992). Recently, a TCR SCFV derived from the TCR of the 
284 T cell hybridoma specific for the C-terminal peptide 
of cytochrome C bound to I-Ek was produced (Kurucz et 
al., 1993). The TCRscFv is indistinguishable antigenically 
from theV region of the native TCR and has binding activity 
to cells expressing MHC-peptide complexes. One disad- 
vantage of scTCRs as well as antibody scFvs is the diffi- 
culty producing these proteins in large quantities and at 
high concentrations because of their tendency to aggre- 
gate (Buchner et al., 1992). To overcome the instability of 
scfvs, we and others have stabilized SCFVS by insertion 
of a disulfide bond between VH and VL (Brinkmann et al., 
1993; Reiter et al., 1994a; Jung et al., 1994; Glockshuber 
et al., 1990). In these disulfide-stabilized Fvs (dsFv), the 
peptide linker connecting VH and VL is replaced by an in- 
terchain disulfide bond engineered into conserved frame- 
work regions of the VH and VL domains of the antibody Fv. 
The positions for the cysteine replacement in antibody 
dsFvs are located in conserved framework regions and 
were used to stabilize various Fvs. The location of the 
cysteines can be identified by a simple sequence homol- 
ogy alignment and without further structural information 
or modeling. Since it has been proposed that Fvs of anti- 
bodies and TCRs have similar structures, we reasoned 
that it should be possible to use positions in the TCR se- 
quence that are homologous to the positions identified for 
disulfide stabilization of antibodies Fvs to make a TCR 
dsFv. The production of such TCRdsFvs would be im- 
portant for two reasons: it should be soluble and stable 
and enable the production of the large amounts required 
for structural analysis; and if disulfide stabilization using 
the same positions that stabilize antibody FVS is success- 
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Figure 1. Disulfide Connection Between Va and Vp of 284 TCR Fv 
Comparison of the variable domains of MAb 83 and 284 TCR. Asterisk 
and open triange, position of cysteine replacements in framework re- 
gions of the TCR(Fv) (Ser-43 in Va and Pro-107 in Vg, or Gin-104 in 
Va and Glu-42 in Vg). The assignment of framework regions l-4 
(FR1-4) and CDRl-3 is according to Kabat et al. (1991). 
ful, it would show that those positions are closely similar 
to the equivalent positions in antibody Fvs, probably within 
less than a 1.5 A discrepancy from the same positions 
in antibody Fv. This would constitute direct experimental 
evidence for the structural identity of antibody and TCR 
Fv framework regions. 
Results 
Design of Dlsulflde Connection Between 
Va and Vfi of 284 TCR Fv 
The two possible positions for disulfide stabilization of anti- 
body Fvs (Reiter et al., 1994a; Jung et al., 1994) are VA4 
and VL-100 and &lo5 and VL-43 (Kabat et al., 1991). 
These two pairs of positions are strictly in the framework 
region of the Fv, distant from the CDRs and with a short 
Ca-Ca distance. We computed the Ca-Ca distances at 
these sites for many Fv regions for which a crystal struc- 
ture is known. These data indicate that this short Ca-Ca 
distance exists for most Fvs and is indeed suitably short 
for the formation of a disulfide bond at the selected sites 
(Jung et al., 1994). To identify the corresponding positions 
in the TCR Fv, we aligned the amino acid sequence of 
antibodies McPC603, J539, and 63 Fv with the 284 TCR 
Fv (Figure 1). We used the BESTFIT sequence alignment 
program in the Genetics Computer Group package (Dev- 
ereux et al., 1994) and visual inspection to align these 
sequences. When the Vu sequence of 284 was aligned 
to the VH sequence, the residue corresponding to the VA4 
site of 83 was identified as Va-43S (TCR 42 in the number- 
ing scheme of Kabat et al., 1991; the Vn-1 05 site of 83 
was identified as Va-104Q VCR 108 in Kabat et al., 19911). 
Similarly, the 284 residues Vf?i 107P and VI3 42E (TCRs 
TCRscFv TCRdsFv 
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Figure 2. Construction of Plasmids for Expression and Production of 
TCR(dsFv)-PE39 
(A) Schematic representation of TCR scFv and TCR dsFv. In the TCR 
dsFv, the (Gly,-Ser), peptide linker is replaced by the designed in- 
terchain disulfide bond. 
(8) Plasmids for expression of TCR(dsFv)-PE39. Single-stranded ura- 
cilcontaining DNA of pYR-TCRl was the template to mutate the identi- 
fied residues to cysteines by mutagenesis. The expression plasmid 
pYR-TCRP for TCR(Va-Cys) was generated by deletion of a Vf3-PE39- 
encoding EcoRl fragment. pYR-TCR3-encoding TCR(Vf&Cys)-PE39 
was constructed by deletion of a Va-encoding Ndel fragment. 
110 and 42 in Kabat et al., 1991) were aligned to antibody 
residues corresponding to VL-1 00 and VL43 of 83, respec- 
tively. We identified the same residues when we aligned 
the Vu of 284 with the VL of McPC603, and VP of 284 
with the VH of McPC603, or when we used the sequence 
of MAb J539 instead of McPC603 for alignment of the 2B4 
sequence. Thus, the potential interchain disulfide bond 
sites are Va43-Vj3107 and ValO4-Vf342. 
Construction of Plasmlds for Expression 
and Production of Dlsulflde-Stabilized 
TCR Fv-PE38 
dsFvs are produced as two separate components, VH and 
VL or Va and Vf3, respectively, which are encoded by sepa- 
rate plasmids and expressed separately (Brinkmann et 
al., 1993; Reiter et al., 1994a). The plasmids, coding for 
(Cys-104)Va and (Cys42)Vf3-PE38 were made by site- 
directed mutagenesis and subcloning from TCRscFv- 
coding plasmid (Figure 28). In the single-chain molecule, 
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Figure 3. SDS-PAGE Analysis on Reducing Gel of the Disulfide- 
Stabilized TCR Fv-PE38 
Lane M, molecular mass standard; lane 1, IBs containing TCR(V8- 
Cys)-PE38; lane 2, TCR(Va-Cys); lane 3, purified TCR(scFv)-PE38; 
lane 4, purified TCR(dsFv)-PE38. Molecular mass standards are (top 
to bottom) 108.80,49.32,27, and 18 kDa, respectively. The gel was 
stained by Coomassie blue. 
the Vu and VP domain8 of the TCR Fv are produced a8 
a single molecule, in which the domain8 are held together 
by a (Gly,-Ser)s peptide linker. In addition to placing the 
cysteine mutation8 in the TCR Fv, we fused a truncated 
fOrtII of Pseudomonas exotoxin (PE38) (Brinkmann et al., 
1993) to the TCR Fv for ease of purification and to facilitate 
subsequent analysis. The TCR(dsFv)-PE36 was ex- 
pressed in intracellular inclusion bodies, and was refolded 
in a redoxshuffling system like antibody dsFv fusions 
(Brinkmann et al., 1993; Reiter et al., 1994a; Figure 3). 
The properly folded TCR(dsFv) fusion was then purified 
to near homogeneity by ion-exchange chromatography 
(Q-Sepharose and Mono Q) followed by size-exclusion 
chromatography (Figure 3). Using this refolding and purifi- 
cation protocol, we obtained -20 mg of purified mono- 
meric TCR(dsFv)-PE38 from 1 I of bacterial culture in- 
duced at ODeoo = 9. From this 1 I, approximately 350 mg 
of protein was present in inclusion bodies, representing 
a yield of 8%. 
SDS-gel analysis of the purified monomeric TCR(dsFv)- 
PE38 protein (Figure 3) indicates homogenous molecules 
composed of only a$ heterodimer with apparent molecu- 
lar mass of 82 kDa as expected. Since the PE39 moiety 
(39 kDa) is fused to the TCR VP, formation of p:p or a:a 
homodimers would result in proteins with an apparent mo- 
lecular mass of - 100 kDa (for p:f3 dimers) or -24 kDa 
(for a:a dimers), respectively, which were not detected 
after purification. 
The Disulfide-Stabilized TCR Fv Retains 
its Native Conformatlon 
The disulfide-stabilized TCR(dsFv)-PE38 that we ob- 
tained has the native conformation of the TCR Fv by two 
criteria; first, it reacts with conformation-specific mono- 
clonal antibodies (MAbs) directed to the V domain of TCR. 
As shown in Figure 4A, the reactivity of TCR(dsFv)-PE38 
and TCR(scFv)-PE38 with MAb RRB-1, specific for Vu1 1, 





Figure 4. Binding of Anti-TCR MAbs to the 284 TCR(dsFv)-PE38 and 
TCR(scFv)-PE38 
The fusion protein were immobilized on 98-well microtiter plates, 
blocked with 1% bovine serum albumin in PBS, and then incubated 
with TCR-specific MAbs. The binding was detected by secondary alka- 
line phosphatase-labeled antibody as described (Kurucz et al., 1993). 
The 284 TCR contains Vall and V83 allotypic determinants (Kurucz 
et al., 1993). A, binding of MAbs to monomeric soluble TCR(dsFv)- 
PE38 and TCR(scFv)-PE38. B, binding of MAbs to aggregated 
TCR(dsFv)-PE38. 
and MAb A2B4, an anti-2B4 idiotype antibody (Kurucz et 
al., 1993), was identical, while a control antibody of the 
same isotype class did not bind to the TCR Fv fusion pro- 
tein. The A284 antibody does not bind to reduced and 
alkylated 2B4TCRscFv because it recognizes aconforma- 
tionally dependent epitope (Kurucz et al., 1993). This anti- 
body also failed to bind to improperly folded aggregated 
forms of TCR(dsFv)-PE38 (Figure 4B). Second, the re- 
folded protein is monomeric in nondenaturing solution 
(see Figure 7) a good indication that the protein has folded 
correctly (Buchner et al., 1992). The fact that MAb A2B4 
recognizes the correctly folded TCRscFv as well as the 
dsFv monomers indicate8 that disulfide stabilization of the 
TCR Fv did not cause significant structural alterations that 
would abolish the specific binding of antibodies directed 
to conformational epitope. 
The TCR(drFv) Is Functional in Cellular Assays 
To test whether the TCR(dsFv) is functional, we studied 
its biological activity in cellular assays in which the inhibi- 
tion of the antigen-specific activation of a T cell hybridoma 
is measured. For these assays, the T cell hybridoma, 284, 
specific for the C-terminal peptide of moth cytochrome c 
bound to I-Ek, was stimulated with suboptimal concentra- 
tions of the antigen moth cytochrome c peptide presented 
by irradiated spleen cells from BIO.A mice, in the absence 
Immunity 
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The 284 T cell hybridoma was stimulated with suboptimal concentra- 
tions of antigenic peptide using irradiated spleen cells from BIO.A 
mice as a source for antigen-presenting cells. This was performed in 
the absence or presence of anti-class II antibody or TCR(dsFv)-PE36. 
T cell activation was monitored by measuring IL-2 secretion. 
or presence of the TCR constructs or anti-MHC class II 
antibody, 14-4-4 (anti I-E”; Ozato et al., 1980). The anti- 
gen-dependent activation or inhibition of the T cell re- 
sponse is measured by the production and secretion of 
interleukin-2 (IL-2). Figure 5 shows peptidedependent ac- 
tivation of the 284 T cell hybridoma that can be inhibited 
efficiently by the anti-class II antibodies. The antigen- 
specific activation was inhibited in adosedependent man- 
ner by the TCR(dsFv) construct (Figure 5). Efficient inhibi- 
tion, which was only 2- to 3-fold lower than the inhibition by 
anti-class II antibody, was obtained at 1 CIM of TCR(dsFv)- 
PE38. The inhibition by the TCR(scFv) and TCR(dsFv) 
constructs was similar (Figure 8), indicating that both TCR 
constructs are functional and disulfide stabilization of the 
TCR(Fv) did not affect its binding capacity as judged by 
these inhibition assays. A control construct of an anti- 
carbohydrate antibody Fv, B3(Fv)-PE38-M, did not have 
any effect on the antigen-specific stimulation of the 2B4 
hybridoma. This control excludes the possible toxic effects 
of the PE38 domain in the TCR(Fv) constructs on the T 
cell hybridoma or spleen cells, even at the high concentra- 
tion of 80 pg/ml required for efficient inhibition of the spe- 
cific T cell response. 
Stability of DlsulfldaStabilizad TCR Fv-PE38 
To test the effect of disulfide stabilization on stability, the 
TCR(dsFv)-PE38, and the TCR(scFv)-PE38 were incu- 
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Figure 6. Comparison of the Activity of TCR(dsFv) and TCR(scFv) in 
Cellular Inhibition Assays 
Assays were performed as described in Figure 5. The inhibitors were 
anti-class II antibody or the TCR(Fv) constructs, TCR(dsFv)-PE36 or 
TCR(scFv)-PEW 
bated at a concentration of 100 pglml in phosphate- 
buffered saline (PBS) at 37’C for various times, and the 
molecular forms of these molecules determined by their 
mobility in size-exclusion chromatography (Figure 7). We 
found that the TCRscFv was unstable, since the mono- 
meric fraction was rapidly converted to aggregates with a 
higher molecular weight. In contrast, the TCRdsFv-fusion 
protein showed no aggregates after 1 hr and only a small 
amount of aggregates after 4 hr. The TCR(scFv)-PE38 
aggregated much more than the TCR(dsFv)-PE38 but 
less than the TCRscFv alone (data not shown). These re- 
sults demonstrate that properly folded TCR(dsFv)-PE38 
molecules have a markedly reduced tendency to aggre- 
gate. This finding is in complete agreement with previous 
observations that disulfide-stabilized Fvs of antibodies are 
more stable than their single-chain counterparts due to a 
reduced tendency of dsFv molecules to aggregate (Reiter 
et al., 1994a, 1994b, 1994c). The cysteine bridge in the 
dsFv apparently helps to maintain the integrity of the mole- 
cule by stabilizing the heterodimer in a correct conforma- 
tion in which it retains its antigen binding capacity. 
Discussion 
We have made a functional disulfide-stabilized Fv of a 
TCR using the same positions that stabilize antibody Fvs. 
These results show that the positions chosen are closely 
similar to the equivalent positions in antibody Fvs, and 
constitute strong direct experimental evidence for the 
structural identity of antibody and TCR Fv framework re- 
gions. The sequence homology between TCR and anti- 
bodies is not especially high. TCR a and p domains have 
an average 25%-30% identity to immunoglobulin VL and 
VH (Claverie et al., 1989). For example, the 284 TCR Va 
and Vp domains share only 200/b-28% identity and 40%- 
48% similarity with the VH and VL domains of antibody 
McPC803. However, the invariant side chains defining the 
Disulfide Stabilization of a TCR Fv 
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Figure 7. Stability of 284 TCA scFv and TCR Fv-PE39 Fusion Pro- 
teins 
TCR(scFv)-PE33 or TCR(dsFv)-PE33 were incubated at 100 kg/ml 
in PBS at 37% for the indicated time. The molecular form of these 
molecules was then analyzed on a TSK3000 size-exclusion chroma- 
tography. Monomers elute at 19-19 ml and aggregates elute at 13- 
14 ml. 
framework of the structure for antibody binding sites are 
shared with the T cell immunoglobulin-like chains, most 
notably the aj3 receptors (Novotny et al., 1966; Claverie 
et al., 1969; Hedrick et al., 1964). The justification for ex- 
pecting a similarity in the three-dimensional structures for 
these molecules is based on the general rule that in the 
evolution of multigene families, such as the immunoglobu- 
lins, protein-folding motifs are even more conserved than 
the amino acid sequence (Novotny et al., 1966). 
The results of the experiments reported here constitute 
strong direct experimental confirmation of this generally 
accepted expectation. The positions used for the disulfide 
stabilization of the TCR Fv were initially identified for anti- 
body Fvs by computer modeling. Afterwards, the appro- 
priate interchain cysteine positions in the 284 TCR Fv 
were identified by simple alignment of TCR and antibody 
sequences without any modeling. Therefore, the success- 
ful formation of the disulfide bond at this site indicates that 
at least the two residues involved, and probably all the 
residues that are equivalent by sequence homology, are 
located at very similar relative positions in the two struc- 
tures. 
How similar? In the case of the antibody 83 Fv, the Ca- 
Ca distance between the pair of residues that could be 
successfully connected by a disulfide bridge is 5.7 A in 
the computer-modeled structure (Jung et al., 1994). The 
corresponding Ca-Ca distances in all known antibody 
structures range from 4.1-6.9 A (Jung et al., 1994). If the 
corresponding Ca-Ca distance in the TCR Fv deviated 
more than this range, a disulfide bond may not form. Re- 
cently, attempts were made to introduce an interchain di- 
sulfide bond in 83 Fv at many sites around the site identi- 
fied by computer modeling. All attempts failed, including 
one for which the Ca-Ca distance is 6.4 A in the computer- 
modeled structure (Y. R., unpublished data). This is rea- 
sonable in view of the fact that the Ca-Ca distance be- 
tween two cysteine residues that form the disulfide bonds 
of the type likely to form at this site is 5.0 A on average 
(Jung et al., 1994; Katz and Kossiakoff, 1966). It can there- 
fore be expected that the mainframe structure of the TCR 
deviates from that of a typical antibody by less than about 
1.5 A (half of the range of variation in the Ca-Ca distances 
given above). 
The ultimate proof for the structural similarity of Fvs of 
antibodies and TCRs will only be provided by solving the 
TCR three-dimensional structure. The possibility of pro- 
ducing large amounts of stable soluble TCR Fv in the form 
of a dsFv should help achieve this goal. The effect of the 
truncated Pseudomonas exotoxin in the fusion proteins 
or the ability to crystalize the protein is not known. How- 
ever, the improved stability of the TCR(dsFv) and recent 
results on stability of antibody dsFvs (Reiter et al., 1994b) 
may enable the production of a TCR(dsFv) alone. 
We also show in this study that the TCR(dsFv) produced 
is functional in cellular assays in which the inhibition of 
the antigen-specific stimulation of a T cell hybridoma is 
measured. The TCR(dsFv) can inhibit in a dose-dependent 
manner T cell stimulation with suboptimal concentrations 
of antigenic peptide. This example demonstrates the func- 
tionality of a TCR(Fv) construct by inhibiting antigen- 
dependent stimulation of T cells. Such inhibitory activity 
was demonstrated previously only by TCR-immunoglobu- 
lin chimeria with the variable and the first constant regions 
of both the TCR a and p chains linked to the immunoglobu- 
lin light chain constant region (Weber et al., 1992). The 
inhibition by TCR(dsFv) and TCR(scFv) constructs was 
similar, inditing that disulfide stabilization of the TCR(Fv) 
did not affect its MHC binding capacity. 
In conclusion, our data provide strong experimental evi- 
dence for the structural identity of TCR and immunoglobu- 
lin Fv antigen binding domains. 
Expsrlmental Procdures 
Ptasmid Constructions 
The parent plasmid for the generation of plasmids for expression of 
TCR(dsFv)-PE33 encodes the single-chain Fv of the 294TCR in which 
the TCR Va and Vf3 domains are held together by a (Gly&erb peptide 
linker and fused to a truncated form of Pseudomonas exotoxin (Kurucz 
et al., 1993). The complete nucleotide sequence of 264 TCR(Fv) has 
beendescribed(Kuruczetal., 1993). Uracilcontainingsingle-stranded 
DNAfrom the F+ origin present in this plasmid was obtained bycotrans- 
fection with Ml3 helper phage and was used as template for site- 
directed mutagenesis as described (Kunkel, 1985). The mutagenic 
oligonucleotides 5’-AACACTCAGAACGGTACCGCAACCAAAAGT- 
CAGCIT-3’ and S-GAACAGATTGATGAGGCAGCCCCGGGAATTC- 
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TGlTGGAA3’were used to change Gin-104 and Ser-43 of 284 TCR 
Va to cysteines, respectively. The oligonucleotides B’GTTAATCAAA- 
AATTTGAAGCAATTGlTCI-TAll-iTG-3’and 5’-TAACACGAGGAGC- 
CGGGTACCGCACCCAAAGTACTGGGT-3’were used to change Glu- 
42 and Pro-107 of 2B4 TCR Vg to cysteines, respsctfvefy. The 
oligcnudeobde 5’-CTGGTACACAGCAGGlTCTGGGTGAAlTCATTAT- 
GGTATAACACTCAGAACGGT3’ was used to introduce stop codnns 
followed by an EcoRl site at the 3’ end of the Va gene and the ofigonu 
deottde 5’CTGAATGACTTfTGAATTCATATGTCCACCCCCTGAGCC 
ACG3’to introduce an Ndel site and ATG translation-initiation codon 
at the N terminus of Vg. Restriction sites were introduced into these 
oligonucleotides to facilitate identification of mutated clones or sub- 
cloning. 
The expression plasmid pYR-TCR2 for TCR(Va-Cys) was generated 
by deletion of a V8-PE38-encoding EcoRl fragment. pYR-TCR3 en- 
coding TCRp&-Cys)-PE38 was constructed by deletion of a Va- 
encoding Ndel fragment. 
Exptusslon, Refolding, and Purltlcatlon 
The components of TCR(dsFv)-PE38, TCR(VaCys) and TCR(Vj3- 
Cys)-PE38 were produced in separate E. coli BL21 SDE3 cultures 
containing the corresponding plasmid. Upon induction with isopropyl- 
8+thiogalactoside, the recombinant proteins accumulate in intracel- 
lular inclusion bodies. The IBs were isolated, solubilized, refolded, and 
purified as described for the preparation of antibody dsFvs (Buchner et 
al., 1992; Brinkmann et al., 1993). 
Slndlng of TCR-Spscltlc MAbs 
The fusion protein were immobilized on 98-well microtiter plates, 
blocked with 1% bovine serum albumin in PBS and then incubated with 
TCR-specific MAbs. The binding was detected by secondary alkaline 
phosphatase-labeled antibody as described (Kuruczet al., 1993). The 
284 TCR contains Vail and V83 allotypic determinants (Kurucz et 
al., 1993). 
Cellular lnhlbttlon Assays 
Irradiated (2409 rads) spleen cells (5 x IOr’) from Bl0.A mice were 
incubated for 24 hr at 37OC with the 2B4T cell hybridoma (2 x IO’) and 
with different concentrations of the antigenic peptide in the presence or 
absence of the TCR(Fv) constructs or anti-class II antibody. Assays 
were done in triplicate in 98well flat-bottomed plates in a final volume 
of 200 ~1. After incubation, collected supernatants were assayed for 
IL-2 production by mouse IL-2 ELISA kit Interset-2X (Genzyme, Incor- 
porated, Cambridge, Massachusetts). Recombinant mouse IL-2 was 
used as a standard. 
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